Regarding platelets, it is not well understood why Fedratinib had the paradoxical effect in reducing thrombocytosis in the PTMF model, as expected from a JAK2 inhibitor, but reducing thrombopenia observed in the PPMF model. The gene discussed is JAK2; the disease is thrombocytosis disease.